SLC5A2 and diabetes mellitus: The DAPA HF (Dapagliflozin in patients with heart failure and reduced ejection fraction), EMPEROR-Reduced (cardiovascular and renal outcomes with Empagliflozin in heart failure) and SOLOIST-WHF (Sotagliflozin in patients with diabetes and recent worsening heart failure) trials showed a significant reduction in the risk of worsening heart failure or death from cardiovascular causes among those taking SGLT2 inhibitors in patients with heart reduced ejection fraction (46–48).